

FOR IMMEDIATE RELEASE

LENSAR APPOINTS PETER J. MARIANI AS CHIEF FINANCIAL OFFICER

Brings Proven Record of Financial Executive Experience with Global Companies Including Hansen Medical and Guidant Corporation

ORLANDO, FLA., September 23, 2014 – LENSAR Inc., a global leader in next-generation femtosecond laser technology for refractive cataract surgery today announced the appointment of veteran financial executive Peter J. Mariani as Chief Financial Officer, effective July 8, 2014. He will report to Nicholas Curtis, LENSAR's Chief Executive Officer.

Mariani has held a variety of financial leadership positions and has extensive international, operational, commercial and capital market experience at public and private companies. From June 2011 to June 2014 Mariani served as Chief Financial Officer at Hansen Medical, a publicly traded medical device company developing intravascular robotic technologies to enable treatment of cardiac arrhythmia and peripheral vascular disease. His experience also includes 12 years in senior financial positions with Guidant Corporation, a global leader in the development and sale of medical devices for the treatment of cardiovascular disease.

"Pete has a strong strategic financial background and a proven track record of results while working for global, private and publicly-traded medical device businesses," said Nick Curtis. "He has a demonstrated track record of developing professional, high-performing teams focused on quality execution, including strategic commercial growth. Additionally, his significant experience with capital markets will serve us well as we continue to expand the development and delivery of our LENSAR Laser System to cataract surgeons worldwide."

Mariani has extensive international, operational and public markets experience, including successful raises of equity, debt and strategic financing. His experience with Guidant Corporation included the initial IPO, as well as two years in their vascular intervention business and four years at Guidant Japan, where he helped facilitate the conversion of Guidant's business in Japan from a distributor network to a direct sales and marketing organization. He then served four years as Guidant's Controller and Chief Accounting Officer. After the 2006 sale of Guidant to Boston Scientific Corporation, Mariani co-led the initial integration of the two companies. He subsequently served as Chief Financial Officer of two private companies, Harlan Laboratories and BMW Constructors.

"I am pleased to join the management team at LENSAR and to have the opportunity to help the Company realize the value of its innovative femtosecond laser cataract technology," Mariani said. "It is an important time for LENSAR as the Company continues to expand the commercial footprint and ensure the clinical adoption of its laser cataract systems."

Mariani began his career at Ernst & Young and served as an audit manager for a variety of public and private clients in many different industries, including healthcare. He has a Bachelor of Science degree in accounting from Indiana University and is a certified public accountant.

About LENSAR, Inc.

LENSAR, Inc. is a global leader in next-generation femtosecond laser technology for refractive cataract surgery. The LENSAR Laser System offers cataract surgeons precision, accuracy, and

efficiency while optimizing overall visual outcomes. LENSAR's proprietary Augmented Reality technology - reconstructed 3-D imaging, measurement, and guidance system – offers quick and easy patient docking and provides high-resolution ocular images in a single scan. This technology facilitates enhanced procedure outcomes by allowing the physician to develop individualized treatment plans including precise laser delivery, and efficient lens fragmentation that can reduce, and potentially eliminate phaco energy. The LENSAR Laser System also offers the industry's smallest laser footprint and thoughtful ergonomic design that accommodates most operating rooms.

The LENSAR Laser System has been cleared by FDA for anterior capsulotomy, lens fragmentation, and corneal and arcuate incisions. For other indications it is an investigational device limited by U.S. law to investigational use only. For more information, please visit www.lensar.com.

###

Media Contact:
Darcy Wendel
dwendel@msn.com
323.842.3963

Investor Inquiries:
Peter J. Mariani, CFO
[\(888\) 536-7271](tel:(888)536-7271)